progressive multifocal leukoencephalopathy
GPTKB entity
Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
central nervous system
|
| gptkbp:associated_with |
immunocompromised individuals
|
| gptkbp:caused_by |
JC virus
|
| gptkbp:clinical_trial |
ongoing studies
investigating stem cell therapy investigating antiviral therapies investigating immune modulation |
| gptkbp:end_of_life |
high in untreated cases
|
| gptkbp:first_described_by |
gptkb:1958
|
| https://www.w3.org/2000/01/rdf-schema#label |
progressive multifocal leukoencephalopathy
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:number_of_teams |
rapid
|
| gptkbp:outcome |
poor prognosis
neurological decline death in severe cases potential for recovery in mild cases quality of life deterioration |
| gptkbp:population |
cancer patients
transplant recipients HIV-positive patients patients on immunosuppressants |
| gptkbp:research_focus |
treatment options
immunological response JC virus behavior |
| gptkbp:risk_factor |
organ transplantation
immunosuppressive therapy certain cancers HIV infection |
| gptkbp:social_responsibility |
gptkb:psychologist
more common in adults MRI scan demyelination acute disseminated encephalomyelitis lesions in white matter |
| gptkbp:symptoms |
cognitive dysfunction
visual disturbances motor weakness |
| gptkbp:treatment |
no effective treatment
|
| gptkbp:bfsParent |
gptkb:Rituxan
|
| gptkbp:bfsLayer |
4
|